This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

KEYNOTE-189: What the 4-year follow-up data might mean for your eligible non-squamous mNSCLC patients

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Licensed indication

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.1

In 2018, the first interim results of the KN-189 study were presented at the American Association for Cancer Research (AACR)2. The most recent 4-year follow up analysis was presented at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) in January 2021.3

We asked Dr Riyaz Shah, a Consultant Medical oncologist at the Kent Oncology Center, for his thoughts on what this latest data might mean for oncologists and their patients.

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 17:03

Recorded in March 2021.

More information about KEYTRUDA:

References

  1. KEYTRUDA Summary of Product Characteristics.
  2. Gandhi L, et al. N Engl J Med 2018: 378: 2078-2092.
  3. Gray J.E., et al. Presented at the 2020 World Conference on Lung Cancer (WCLC), January 28 – 31, 2021.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01576 | Date of Preparation: July 2021